Clinical Trial

Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy

Study acronym: PA-SELECT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-15; most recent amendment 2025-04-14.
Status change: Not Yet Recruiting → Recruiting 2024-08-23
Trial Details
NCT Number NCT06513585
Lead Sponsor Xinjiang Medical University
Collaborators: First Affiliated Hospital of Xinjiang Medical University
Conditions Primary Aldosteronism, Suprarenalectomy, Super Selective Adrenal Artery Embolization
Enrollment 570 participants
Start Date 2024-08-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-15